Teva acquires Tourette therapy ecopipam for ~$700M, raises 2026 outlook on innovative brands

Filed July 29, 2026 · Period ending July 29, 2026 · ~1 min read

Key Changes

• high

  Acquired Emalex Biosciences and ecopipam (first-in-class Tourette therapy) for ~$700M cash; NDA submitted to FDA June 2026, accelerating late-stage neuroscience pipeline

  Exhibit 99.1 view on EDGAR →
• high

  Raised 2026 revenue outlook for key innovative brands (AUSTEDO, AJOVY, UZEDY) to ~$3.7B combined, reflecting ~17% YoY growth at mid-point

  Exhibit 99.1 view on EDGAR →
• high

  Q2 2026 revenues $4.1B (down 1% YoY), but three key innovative brands grew 43% YoY in local currency to over $1B, offsetting generic declines

  Exhibit 99.1 view on EDGAR →